MX2019003945A - Formas cristalinas y salinas de compuestos agonistas de ppar. - Google Patents
Formas cristalinas y salinas de compuestos agonistas de ppar.Info
- Publication number
- MX2019003945A MX2019003945A MX2019003945A MX2019003945A MX2019003945A MX 2019003945 A MX2019003945 A MX 2019003945A MX 2019003945 A MX2019003945 A MX 2019003945A MX 2019003945 A MX2019003945 A MX 2019003945A MX 2019003945 A MX2019003945 A MX 2019003945A
- Authority
- MX
- Mexico
- Prior art keywords
- salt forms
- crystalline
- agonist compounds
- ppar agonist
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta divulgacion se relaciona con formas salinas de compuestos que tienen capacidad para activar PPARd para su uso en el desarrollo de farmacos y productos farmacologicos, y composiciones y metodos relacionados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055403 WO2018067860A1 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003945A true MX2019003945A (es) | 2019-09-18 |
| MX385973B MX385973B (es) | 2025-03-18 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003945A MX385973B (es) | 2016-10-05 | 2017-10-05 | Formas cristalinas y salinas de compuestos agonistas de ppar |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (es) |
| EP (1) | EP3523283B1 (es) |
| JP (1) | JP7017563B2 (es) |
| KR (1) | KR20190057129A (es) |
| CN (1) | CN109843857B (es) |
| AU (1) | AU2017340763B2 (es) |
| CA (1) | CA3036587A1 (es) |
| CO (1) | CO2019003162A2 (es) |
| CY (1) | CY1124655T1 (es) |
| DK (1) | DK3523283T3 (es) |
| ES (1) | ES2887008T3 (es) |
| HR (1) | HRP20211341T1 (es) |
| HU (1) | HUE055678T2 (es) |
| IL (1) | IL265730B (es) |
| JO (1) | JOP20190039B1 (es) |
| LT (1) | LT3523283T (es) |
| MA (1) | MA46460A (es) |
| MX (1) | MX385973B (es) |
| MY (1) | MY202008A (es) |
| PH (1) | PH12019500727A1 (es) |
| PL (1) | PL3523283T3 (es) |
| PT (1) | PT3523283T (es) |
| RS (1) | RS62245B1 (es) |
| RU (1) | RU2759724C2 (es) |
| SG (1) | SG11201901995TA (es) |
| SI (1) | SI3523283T1 (es) |
| TW (1) | TWI769182B (es) |
| UA (1) | UA124770C2 (es) |
| WO (1) | WO2018067860A1 (es) |
| ZA (1) | ZA201901744B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2325171B1 (en) | 2005-05-26 | 2013-10-09 | Aldexa Therapeutics, Inc. | Quinoline derivatives for treating retinal diseases |
| US9814701B2 (en) | 2009-12-11 | 2017-11-14 | Aldeyra Therapeutics, Inc. | Compositions and methods for the treatment of macular degeneration |
| CN105120866B (zh) | 2013-01-23 | 2020-02-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| MX392524B (es) * | 2015-10-07 | 2025-03-24 | Salk Inst Biological Studies | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
| CN109843857B (zh) | 2016-10-05 | 2023-01-06 | 米托布里奇公司 | Ppar激动剂化合物的结晶和盐形式 |
| US11040039B2 (en) | 2017-10-10 | 2021-06-22 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
| JP2021533154A (ja) * | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| EP3871667A4 (en) * | 2018-10-23 | 2022-08-17 | Japan Science and Technology Agency | PPAR DELTA ACTIVATOR |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2020223685A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| JP2023526016A (ja) | 2020-05-13 | 2023-06-20 | アルデイラ セラピューティクス， インコーポレイテッド | 医薬製剤およびその使用 |
| JP2024521353A (ja) | 2021-06-02 | 2024-05-31 | アステラス製薬株式会社 | Ｐｐａｒアゴニスト化合物の使用法およびその薬学的組成物 |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| WO2025207099A1 (en) * | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060241157A1 (en) | 2003-01-06 | 2006-10-26 | Conner Scott E | Heterocyclic ppar modulators |
| EP1671633A1 (en) | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Use of PPAR agonists for the treatment of congestive heart failure |
| MX2007009356A (es) | 2005-02-03 | 2007-12-07 | Irm Llc | Compuestos y composiciones como moduladores de ppar. |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| DE102006023336A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| FR2940289B1 (fr) | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| WO2016057658A1 (en) | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| MX392524B (es) * | 2015-10-07 | 2025-03-24 | Salk Inst Biological Studies | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
| RU2746602C2 (ru) | 2016-04-13 | 2021-04-16 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| CN109843857B (zh) | 2016-10-05 | 2023-01-06 | 米托布里奇公司 | Ppar激动剂化合物的结晶和盐形式 |
| JP7065839B2 (ja) | 2016-10-05 | 2022-05-12 | ミトブリッジ，インコーポレーテッド | 急性腎障害を処置する方法 |
-
2017
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/en active Active
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/en not_active Ceased
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Ceased
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 CA CA3036587A patent/CA3036587A1/en active Pending
- 2017-10-05 MX MX2019003945A patent/MX385973B/es unknown
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003945A (es) | Formas cristalinas y salinas de compuestos agonistas de ppar. | |
| UY37036A (es) | Compuestos inhibidores de la quinasa de unión a tank | |
| ES2897914T8 (es) | Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos | |
| DK3190113T3 (da) | Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist | |
| CL2018000819A1 (es) | Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| BR112016015706A2 (pt) | composto, uso do mesmo e composição farmacêutica | |
| BR112016000489A2 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| PT3177659T (pt) | Compostos contendo azoto, adequados para uso na preparação de poliuretanos | |
| CO2017002160A2 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| SI3481846T1 (sl) | 11-substituirani 24-hidroksisteroli za uporabo pri zdravljenju stanj, povezanih z NMDA | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| CL2014003612S1 (es) | Peine para aparato de aseo | |
| CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| MX373268B (es) | Compuestos ppar para uso en el tratamiento de enfermedades fibroticas. | |
| CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| CL2018003143A1 (es) | Compuesto de dihidroisoxazol para uso en el control de piojos de mar | |
| CL2015003433A1 (es) | Derivados de tilosina y método para su preparación | |
| ES2523418R2 (es) | Procedimiento de obtencion de composiciones protegidas para alimentacion animal, composiciones y uso de las mismas | |
| BR112018005299A2 (pt) | 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso |